OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (March 2011)
14 slides from OncoSec Medical's investor presentation, Mar 16, 2011
Slide 1: OncoSec Medical: Electro-Oncology
Onc: Sec Medical Electro-Oncology Precision Tumor Destruction, Enhanced Patient Quality of Life OTCBB: ONCS(D) Punit Dhillon President & CEO OnC2:S@C medical
Slide 2: Forward Looking Statement
Forward Looking Statement Our commentary and responses to your questions may contain forward- looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of OncoSec’s te
Slide 3: Investment Overview
Investment Overview Problem • Over 5 million (est.) people in the US with difficult to treat tumors • Current treatments have drastic negative cosmetic and functional outcomes Solution • OncoSec’s treatment platforms to target cancer tissue and margins to selectively destroy cancer cells while leavi
Slide 4: OncoSec System
OncoSec System • Drug-device combination • Razor-razorblade marketing strategy • Mode of therapy • Locally injected low dose bleomycin plus electroporation to kill cancer cells in tumors and leaves the healthy margin surrounding the tumor intact • Patent estate • Electric pulse generators and applic
Slide 5: Electro-Oncology Therapy: Precision and Efficacy
Electro-Oncology Therapy: Precision and Efficacy Bleomycin injected directly Tumor mass electroporated: drug into tumor: targeted therapy uptake > 6000 fold over natural state Electroporation: millisecond pulses increase cell permeability Cell membrane Cell membrane Cell membrane prior to pulsing du
Slide 6: Positive Data from Late Stage Clinical Trials
Positive Data from Late Stage Clinical Trials • Two pivotal multinational Phase III trials • Recurrent squamous cell carcinomas of the head and neck (SCCHN) • United States, Canada, Eastern and Western Europe • European, open-label Phase IV SCCHN study • European, open-label Phase IV skin cancer stu
Slide 7: Treatment of a Head & Neck Cancer
Treatment of a Head & Neck Cancer Lateral tongue cancer Chemo-electroporation Tumor Electroporation injected applied with with bleomycin applicator 1 day post-chemo-electroporation 4 wks post-chemo-electroporation No Cancer cells removal destroyed of while healthy preserving tissue healthy margin Co
Slide 8: OncoSec Competitive Advantages
OncoSec Competitive Advantages Compelling stakeholder benefits and promise of market pull • Improved cosmetic, functional and pain outcomes → patient preference • Minimal tissue removal = simple post-op care → physician & payor preference • Transcends tumor types & locations → physician preference •
Slide 9: Electro-Immuno Therapy: US Phase II Melanoma
Electro-Immuno Therapy: US Phase II Melanoma • Delivery of DNA encoded for cytokines by OncoSec electroporation stimulated the immune system in target tissue • No unwanted immune response against the agent or systemic toxicity, a challenge for both high-dose cytokine and non-DNA immune therapeutics
Slide 10: Commercialization Strategy
Commercialization Strategy • Leverage large historical patient database • Conduct US pivotal trials for skin cancers with unmet clinical need beginning later this year • Extend EU pre-marketing (Phase IV) studies demonstrating pharmacoeconomic, reimbursement, and QoL benefits • Develop “electro-immu
Slide 11: Board of Directors
Board of Directors • Dr. Avtar Dhillon, MD – Co-founder, Chairman, Independent Director • Executive Chairman, Inovio Pharmaceuticals, Inc. (President & CEO, 2001-2009) • Partnering, M&A, finance, turnaround and restructuring experience (previous turnaround of Cardiome) • Raised over $200 million for
Slide 12: Management Team
Management Team • Punit Dhillon – Co-founder, President & CEO • Dr. Michael Cross, Ph.D. – Co-founder, Chief Operating Officer • 20 years in VC (MDS Capital, Jovian Capital, GrowthWorks) and biotech operations: MDS Inc (Director), MDS Proteomics (VP), Viventia Biotech (COO) - experience financing an
Slide 13: Planned Milestones Next 12 Months
Planned Milestones Next 12 Months Q2 Complete asset purchase agreement with Inovio Pharmaceuticals • New management and Board of Directors appointments Q3 • Re-establish CE Mark • Pre-IND FDA Meeting for cutaneous cancer indication • Launch immunotherapy based Phase II melanoma study (IL-12) • Est
Slide 14: Business Opportunity Summary
Business Opportunity Summary $1B market for locally effective, tissue sparing tumor treatment Cancer therapy using small molecules and biologics: diversified Market exclusivity through potential orphan indications CE certified in Europe Market ready with favorable pharmacoeconomics & quali